NOV 28, 2016 06:53 PM PST

By Exploiting a Weakness in Genetic Code, RNA Virus is Attenuated

WRITTEN BY: Carmen Leitch
By using a vulnerability they found in the genetic code of venezuelan equine encephalitis virus (VEEV), researchers were able to mutate VEEV and create a much less deadly mutant virus. The scientists hope this version of the virus and their methodology, published in the Journal of Virology, will open up avenues for the design of a vaccine or therapeutic drugs to fight VEEV.
Photomicrograph of mouse brain tissue after dying of Venezuelan Encephalitis. Reveals neural necrosis and edema. /Credit: CDC's Public Health Image Library (PHIL)
Venezuelan equine encephalitis virus is a deadly disease for infected donkeys, horses, and zebras, and has a mortality rate that can reach 80 percent in affected animals. Symptoms include catastrophic and rapid brain swelling that has serious neurological effects. It can even cause sudden death. Infected humans experience similar symptoms. The VEEV virus was weaponized by both the United States and the Soviet Union, and as such has been classified as a category B pathogen – an agent that is in the second highest risk group when assessing dangers to national security and public safety.

VEEV is an RNA virus, which means that instead of DNA as genetic material, it has RNA. Many dangerous viruses that are serious threats to public health are also RNA viruses with similar weaknesses in their codes. Research into the development of therapeutics for such viruses like Zika and HIV may benefit greatly from this work.
"RNA viruses tend to cause acute infections," explained senior author of the study Jonathan Dinman, Professor and Chair of the UMD Department of Cell Biology and Molecular Genetics. "You either fight them off quickly, like the common cold, or they overwhelm you, like Ebola."
The researchers used a mechanism that enables RNA viruses to put a lot of genetic information into a bit of RNA; it’s called programmed ribosomal frameshifting (PRF) – animation seen below. PRF makes an infected cell read the same RNA sequence in two different phases, so a virus can thus create two different proteins rather than one from the same genetic information.

The researchers disrupted PRF by mutating the genetic code of VEEV and disrupted the mechanism that makes a second protein from one piece of RNA. Cells grown in culture did not show much change how fast the virus was produced. After testing the mutant virus in lab mice, they observed a significant increase in ability of infected mice to survive the disease.
"With some simple mutations, we compromised VEEV's ability to be a virulent virus," commented the lead author, Joe Kendra, a biological sciences graduate student at UMD. "This result shows that PRF might be a therapeutic target for other viruses. If we can confirm that the mutant virus confers immunity, opening the door to a vaccine, that will be very exciting."
Not only was there a higher survival rate in mice carrying mutant VEEV, less of the virus was seen accumulating in tissues of the brain. The researchers suggest mutant virus lacks a protein that enables it to cross the blood-brain barrier - a precursor to brain swelling.
"It's interesting that the virus uses PRF to survive, but we can also manipulate that mechanism to work against it," said study co-author Yousuf Khan, a Goldwater Scholar at UMD. "This is a new way to target viruses and make vaccines. It opens up a lot of new research questions."
According to Dinman, this data is especially interesting because as the threat of climate change looms, such viral threats may begin to reach areas further north.
"So many of these diseases are borne by mosquitoes. Chikungunya is now established in the Caribbean, and Zika has been found in two counties in Florida," said Dinman. "These viruses are on our doorstep. But these results give us hope. Developing a vaccine takes a long time, but with a concerted effort across government and academic labs, we have a good chance."

If you’d like to know more about diseases of equine encephalitis, watch the short video.
Sources: AAAS/Eurekalert via University of Maryland, NIAID, Journal of Virology
About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 13, 2018
AUG 13, 2018
Silent Viruses Impact Microbe and Immune Cell Populations
Subclinical infections may alter the immune system and gut microbiota in the human host impacting how we respond to environmental stimuli like vaccines....
SEP 12, 2018
Genetics & Genomics
SEP 12, 2018
Tightening Control of Bacterial Gene Expression
Controlling gene expression will improve the production of important molecules in bacteria, like therapeutics or biofuels....
SEP 26, 2018
SEP 26, 2018
What Superbug? A New Antibiotic Contender
Scientists from a biotechnology corporation, Genentech, have altered a protein that blocks a signaling pathway in gram-negative bacteria to engineer a new antibiotic, currently called G0775,...
OCT 02, 2018
Drug Discovery
OCT 02, 2018
Mycobacterial Lung Disease, FDA Approves New Drug
New drug seeking to treat antibiotic-resistant lung disease has just been approved by the U.S. Food and Drug Administration. The drug is called ‘Arik...
OCT 08, 2018
OCT 08, 2018
Is a Virus Causing a Mysterious Polio-like Illness in Kids?
Sometime in 2014, the CDC began to get reports of a mysterious illness that was affecting children. More cases have appeared since then....
OCT 11, 2018
Cell & Molecular Biology
OCT 11, 2018
Revealing a 'Double Agent' in the Immune System
Researchers want to enhance our natural defenses to fight a variety of health problems more effectively....
Loading Comments...